Kalaris Therapeutics, Inc.
KLRS
$3.45
-$0.02-0.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.37M | 4.26M | 3.64M | 3.62M | 3.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.39M | 11.83M | 10.80M | 12.74M | 12.26M |
| Operating Income | -12.39M | -11.83M | -10.80M | -12.74M | -12.26M |
| Income Before Tax | -11.52M | -10.86M | -10.00M | -11.89M | -11.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.52M | -10.86M | -10.00M | -11.89M | -11.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.52M | -10.86M | -10.00M | -11.89M | -11.35M |
| EBIT | -12.39M | -11.83M | -10.80M | -12.74M | -12.26M |
| EBITDA | -12.38M | -11.82M | -10.79M | -12.74M | -- |
| EPS Basic | -0.48 | -0.46 | -0.51 | -0.64 | -0.61 |
| Normalized Basic EPS | -0.30 | -0.29 | -0.32 | -0.40 | -0.38 |
| EPS Diluted | -0.48 | -0.46 | -0.51 | -0.64 | -0.61 |
| Normalized Diluted EPS | -0.30 | -0.29 | -0.32 | -0.40 | -0.38 |
| Average Basic Shares Outstanding | 23.80M | 23.72M | 19.45M | 18.70M | 18.70M |
| Average Diluted Shares Outstanding | 23.80M | 23.72M | 19.45M | 18.70M | 18.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |